Predict your next investment

Corporation
fosunpharma.com

See what CB Insights has to offer

Investments

38

Portfolio Exits

12

Partners & Customers

10

About Fosun Pharmaceutical

Fosun Pharmaceutical strategically covers a number of important aspects of the pharmaceutical health industry chain, from research and development, pharmaceutical manufacturing, medical diagnosis and medical equipment to pharmaceutical distribution and retail and medical services, to contribute to public health.

Fosun Pharmaceutical Headquarter Location

Fosun Commercial Building No.2 Fuxing Road (East)

Shanghai, Shanghai, 200010,

China

+86-21-23138000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fosun Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Fosun Pharmaceutical in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Research containing Fosun Pharmaceutical

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Fosun Pharmaceutical in 1 CB Insights research brief, most recently on Mar 6, 2019.

Latest Fosun Pharmaceutical News

Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

Oct 12, 2021

distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR Lugano, Switzerland – Shanghai, China, October 12, 2021 - Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Fosun Pharmaceutical A.G., a corporation organised and existing under the law of Switzerland and a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), a leading global pharmaceutical and healthcare provider in China, announced today the signing of exclusive license and distribution agreements effective from October 1st 2021 in the territory of Mainland China for Aloxi®, Akynzeo® and anamorelin. Under the terms of the agreements, Helsinn will grant Fosun Pharmaceutical A.G. an exclusive license to distribute, promote, market, and sell the following products in the aforesaid territory: Approved products: Aloxi® (Palonosetron hydrochloride) for the prevention of Chemotherapy Induced Nausea and Vomiting (CINV) and for Post-Operative Nausea and Vomiting Akynzeo® oral (Netupitant and Palonosetron hydrochloride) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and with moderately emetogenic cancer chemotherapy Products under development NEPA (Fosnetupitant and Palonosetron hydrochloride) IV, which is being developed in China for the prevention of CINV anamorelin, a selective, novel, orally active ghrelin receptor agonist, which is being developed for the treatment of Malignancy Associated Weight Loss and Anorexia in non-small cell lung cancer patients Helsinn will also grant Fosun Pharmaceutical A.G. an exclusive license for the said products in Hong Kong SAR and Macau SAR. In addition, Helsinn’s Chinese subsidiary, Helsinn Pharmaceuticals Beijing Co. Ltd. (HPC) will provide Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a subsidiary company of Fosun Pharma with certain medical, marketing and commercial services, including co-promotion services in Shanghai, China, in support to the commercialization of the products in Mainland China, Hong Kong SAR and Macau SAR. Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Delivering therapies and supportive care to those living with cancer is at the core of what we do here at Helsinn, and we are pleased to have found a partner in Fosun Pharmaceutical A.G. that shares our values. Through these agreements we are able to provide patients across Mainland China and other territories with much needed therapies, targeting a variety of cancer-related illnesses and we look forward to working closely with Fosun Pharma in doing so.” Wu Yifang, Chairman and CEO of Fosun Pharma, commented: “We are very pleased to sign this agreement with Helsinn. At Fosun, we are passionate about providing better health solutions for patients and these exclusive license and distribution agreements for Aloxi®, Akynzeo® and anamorelin across Mainland China, Hong Kong SAR and Macau SAR show our commitment to that mission. We are looking forward to working with Helsinn and to making these therapies available to patients in these territories as soon as possible.” About Aloxi® in China Palonosetron hydrochloride injection (strength: 5 ml/ 0.25 mg as Palonosetron) is indicated in adults for prevention of acute nausea and vomiting associated with Highly emetogenic cancer chemotherapy and Moderately emetogenic cancer chemotherapy. This product is indicated in pediatric patients aged 1 month to less than 17 years for: Prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Soft Capsules (0.5 mg as Palonosetron) is indicated for the prevention of acute nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron hydrochloride injection (strength: 1.5 ml/0.075 mg as Palonosetron) is indicated in adults for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. About Akynzeo® oral in China Netupitant and palonosetron hydrochloride capsules is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and with moderately emetogenic cancer chemotherapy. NEPA (Fosnetupitant and Palonosetron hydrochloride) IV The product containing 235 mg of fosnetupitant (equivalent to 260 mg fosnetupitant chloride hydrochloride) and 0.25 mg of palonosetron (equivalent to 0.28 mg of palonosetron hydrochloride) is being developed in China for prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy. About anamorelin Anamorelin is a selective, novel, orally active ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism. Anamorelin is an investigational agent, which is being developed for the treatment of Malignancy Associated Weight Loss and Anorexia in non-small cell lung cancer patients. Anamorelin is not approved by the China National Medical Products Administration (“NMPA”). About the Helsinn Group Helsinn is a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, thanks to a consolidated track record, a solid revenue stream in B2B and strong cash flow and cash position. Helsinn is building market differentiation in B2C in the U.S. and China and is owned by a third-generation healthcare entrepreneurial family. Since 1976, Helsinn has been improving the lives of patients, guided by core family values of respect, integrity and quality and through a unique integrated licensing business model, and by collaborating with success in about 190 countries with long-standing partners, who share our values. The Group’s pharmaceutical business (Helsinn Healthcare S.A.) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics (U.S.), Inc.) and China (Helsinn Pharmaceuticals (Beijing) Co., Ltd) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis S.A., an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals Ltd, a drug product manufacturer). Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company’s strategic plan by a commitment to sustainable growth. To learn more about Helsinn Group please visit  www.helsinn.com About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading global pharmaceutical and healthcare provider in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through its associated company Sinopharm Co., Ltd., Fosun Pharma’s business extends to pharmaceutical distribution and retail. Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability. Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry. For more information, please visit: www.fosunpharma.com For more information:

Fosun Pharmaceutical Investments

38 Investments

Fosun Pharmaceutical has made 38 investments. Their latest investment was in Haoxinqing as part of their Series B on September 9, 2021.

CBI Logo

Fosun Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/7/2021

Series B

Haoxinqing

$30.93M

Yes

5

7/28/2021

Seed

Hepa Thera Bio

$4.62M

Yes

2

7/19/2021

Corporate Minority - II

Shenli Technology

Yes

1

5/20/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/26/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/7/2021

7/28/2021

7/19/2021

5/20/2021

3/26/2021

Round

Series B

Seed

Corporate Minority - II

Series C

Series C

Company

Haoxinqing

Hepa Thera Bio

Shenli Technology

Subscribe to see more

Subscribe to see more

Amount

$30.93M

$4.62M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

2

1

10

10

Fosun Pharmaceutical Portfolio Exits

12 Portfolio Exits

Fosun Pharmaceutical has 12 portfolio exits. Their latest portfolio exit was Tianjin Pharmaceutical Group on August 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/23/2021

Corporate Majority

$991

1

8/20/2021

IPO

1

6/18/2021

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

8/23/2021

8/20/2021

6/18/2021

00/00/0000

00/00/0000

Exit

Corporate Majority

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Fosun Pharmaceutical Acquisitions

13 Acquisitions

Fosun Pharmaceutical acquired 13 companies. Their latest acquisition was abcarta on August 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/20/2021

Series A

Corporate Majority

1

9/17/2020

$991

Acquired

1

9/8/2020

Corporate Majority

Corporate Majority

1

10/30/2017

Subscribe to see more

$991

$99M

Subscribe to see more

10

9/18/2017

Corporate Majority

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

8/20/2021

9/17/2020

9/8/2020

10/30/2017

9/18/2017

Investment Stage

Series A

Corporate Majority

Corporate Majority

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$99M

$99M

Note

Corporate Majority

Acquired

Corporate Majority

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Fosun Pharmaceutical Partners & Customers

10 Partners and customers

Fosun Pharmaceutical has 10 strategic partners and customers. Fosun Pharmaceutical recently partnered with Suzhou Kintor Pharma on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/15/2021

Partner

Suzhou Kintor Pharma

China

Kintor Pharmaceutical Collaborates With Fosun Pharma Development To Commercialise Proxalutamide For Treatment Of COVID-19 In India And Africa

SUZHOU , China , July 14 , 2021 / PRNewswire / -- Kintor Pharmaceutical Limited today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. , on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries .

3

4/27/2021

Licensor

Revance Therapeutics

United States

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

`` The initiation of Phase 3 clinical trials for the treatment of glabellar lines and cervical dystonia marks an important advancement in our international expansion efforts and partnership with Fosun Pharma Industrial , '' said Mark J. Foley , President and Chief Executive Officer at Revance Therapeutics , Inc. .

2

8/31/2020

Licensor

Polyphor

Switzerland

Polyphor : and Fosun Pharma announce exclusive licensing agreement for balixafortide in China

Polyphor and Fosun Pharma announce exclusive licensing agreement for balixafortide in China

4

3/15/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/18/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/15/2021

4/27/2021

8/31/2020

3/15/2020

11/18/2019

Type

Partner

Licensor

Licensor

Partner

Licensor

Business Partner

Suzhou Kintor Pharma

Revance Therapeutics

Polyphor

Country

China

United States

Switzerland

Subscribe to see more

Subscribe to see more

News Snippet

Kintor Pharmaceutical Collaborates With Fosun Pharma Development To Commercialise Proxalutamide For Treatment Of COVID-19 In India And Africa

SUZHOU , China , July 14 , 2021 / PRNewswire / -- Kintor Pharmaceutical Limited today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. , on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries .

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

`` The initiation of Phase 3 clinical trials for the treatment of glabellar lines and cervical dystonia marks an important advancement in our international expansion efforts and partnership with Fosun Pharma Industrial , '' said Mark J. Foley , President and Chief Executive Officer at Revance Therapeutics , Inc. .

Polyphor : and Fosun Pharma announce exclusive licensing agreement for balixafortide in China

Polyphor and Fosun Pharma announce exclusive licensing agreement for balixafortide in China

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

2

4

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.